NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative
Iovance Biotherapeutics (IOVA) recently refreshed its corporate presentation, spotlighting tumor infiltrating lymphocyte therapies, more than 1,500 patients treated, over 90 treatment centers, and revenue guidance for Amtagvi in advanced melanoma.
See our latest analysis for Iovance Biotherapeutics.
The refreshed Iovance Biotherapeutics story has been accompanied by strong momentum, with a 12.63% 1 month share price return and a 73.41% year to date share price return, while the 1 year total...